Compare Thomson Reuters Corp (TRI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Twist Bioscience Corp — how do they compare? Thomson Reuters Corp trades at $90.7 (market cap $41.28B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Thomson Reuters Corp is far larger — about 7.6× Twist Bioscience Corp's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TRI | TWST | |
|---|---|---|
Market Cap | $41.28B | $5.45B |
Sector | Industrials | Health |
52-Week High | $205.54 | $102.88 |
52-Week Low | $76.55 | $24.16 |
Enterprise Value | $43.24B | $5.37B |
Dividend Yield | 2.75% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
